Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA increased its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 3.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 269,741 shares of the company’s stock after purchasing an additional 9,054 shares during the period. Massachusetts Financial Services Co. MA owned 0.20% of Organogenesis worth $755,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in ORGO. Assenagon Asset Management S.A. boosted its position in shares of Organogenesis by 309.3% in the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock worth $11,136,000 after buying an additional 3,005,450 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Organogenesis in the 1st quarter worth approximately $1,846,000. Acadian Asset Management LLC boosted its holdings in Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock worth $8,521,000 after acquiring an additional 471,741 shares during the period. Wealth Dimensions Group Ltd. grew its position in Organogenesis by 435.9% in the second quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock valued at $1,142,000 after acquiring an additional 331,840 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of Organogenesis by 102.8% during the first quarter. GSA Capital Partners LLP now owns 531,218 shares of the company’s stock valued at $1,509,000 after purchasing an additional 269,315 shares during the period. 49.57% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Lake Street Capital began coverage on shares of Organogenesis in a research note on Friday, June 28th. They issued a “buy” rating and a $5.00 target price for the company.

Organogenesis Trading Down 3.4 %

Shares of ORGO opened at $2.83 on Monday. Organogenesis Holdings Inc. has a one year low of $1.96 and a one year high of $4.70. The stock has a 50-day moving average price of $2.80 and a 200 day moving average price of $2.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.42 and a current ratio of 2.73. The company has a market capitalization of $375.18 million, a P/E ratio of 70.75 and a beta of 1.62.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. The business had revenue of $130.23 million during the quarter, compared to analyst estimates of $122.48 million. Sell-side analysts forecast that Organogenesis Holdings Inc. will post -0.19 EPS for the current fiscal year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.